Latest 10-K annual reports

STRATS Trust for Procter & Gamble Securities, Series 2006-1 files its annual report on Form 10-K, disclosing a material instance of noncompliance related to investor remittances.

First Capital, Inc. reports a slight decrease in net income for FY24, accompanied by strategic balance sheet adjustments and increased focus on commercial lending.

Humacyte, Inc. announced FDA approval for its bioengineered tissue product Symvess for extremity vascular trauma and initiated its U.S. commercial launch in Q1 2025, while continuing Phase 3 trials for other indications and securing significant financing.

STRATS Trust For Dominion Resources, Inc. Securities, Series 2005-6 files its annual report on Form 10-K, detailing compliance with trust agreements and incorporating distribution statements.

Scilex Holding Company's 10-K filing highlights its focus on non-opioid pain management through commercialized products and pipeline development.

Avalon GloboCare Corp. files its annual report on Form 10-K, detailing its financial performance, strategic shifts towards precision diagnostic consumer products, and a pending merger with YOOV Group Holding Limited.

Galera Therapeutics pivots to breast cancer drug development following the acquisition of Nova Pharmaceuticals, focusing on aggressive subtypes like metaplastic breast cancer.

REGO Payment Architectures, Inc. files its 10-K for 2024, highlighting its focus on monetizing the Mazoola digital wallet platform and expanding into new markets while addressing ongoing financial challenges.

Byrna Technologies files an amendment to its annual report on Form 10-K to include information regarding directors, executive officers, corporate governance, executive compensation, and principal accounting fees.

STRATS Trust For Wal-Mart Stores, Inc. Securities, Series 2005-4 files its annual report on Form 10-K for the fiscal year ended December 31, 2024, detailing compliance with the trust agreement and incorporating distribution reports.

Petros Pharmaceuticals discontinues Stendra sales and pivots towards developing a proprietary OTC technology platform while facing significant financial hurdles and going concern doubts.

Omeros Corporation's 10-K filing reveals substantial doubt about its ability to continue as a going concern, even as it resubmits its BLA for narsoplimab in TA-TMA and advances other clinical programs.

Thunder Mountain Gold, Inc. files its annual report on Form 10-K/A, highlighting exploration activities at the South Mountain Project and a private placement financing.

Harvard Apparatus Regenerative Technology reports a going concern qualification due to recurring losses and the need for additional funding, while facing delays in patient recruitment for its esophageal regeneration clinical trial.

STRATS Trust For United States Cellular Corporation Securities, Series 2004-6 files its annual report, confirming compliance with trust agreements for the year ended December 31, 2024.

Duos Technologies Group expands into edge computing and power generation while managing existing rail technology deployments, aiming for profitability in 2025.

Eagle Financial Services, Inc. announces a significant increase in net income for 2024, fueled by strategic initiatives and improved operational efficiency.

Birchtech Corp. announces its annual results for the year ended December 31, 2024, including a restatement of prior periods due to revenue recognition errors, and provides an update on its mercury emissions and water treatment businesses.

Biomea Fusion's 10-K filing reveals a strategic shift towards diabetes and obesity treatments, alongside a leadership transition and updates on clinical programs.

Soluna Holdings outlines its 2024 performance and strategic shift towards AI infrastructure, while addressing financial challenges and market volatility.

Dragonfly Energy Holdings Corp.'s 10-K filing outlines the company's capital stock structure, including common and preferred stock, warrant details, and anti-takeover measures.

Metal Sky Star Acquisition Corporation's annual report reveals ongoing efforts to secure a business combination amidst financial challenges and potential Nasdaq delisting.

Mitesco, Inc. files its 10-K report for the year ended December 31, 2024, highlighting a strategic shift towards data center services and AI development while managing significant debt through restructuring.

Vivos Therapeutics pivots towards strategic alliances and acquisitions to drive revenue growth after mixed results in 2024.

Albemarle Corporation files an amendment to its 2024 annual report to include the financial statements of Windfield Holdings Pty Ltd as required by SEC regulations.

China Pharma Holdings reports a decline in revenue for fiscal year 2024 due to increased competition and regulatory changes in the Chinese pharmaceutical market.

Kennedy-Wilson Holdings files an amendment to its 2024 annual report to include the financial statements of Vintage Housing Holdings, LLC, as required by SEC regulations.

VolitionRx Limited appoints Timothy Still as non-executive Chairman of the Board, detailing his responsibilities, compensation, and the company's commitment to indemnification and insurance.

Velo3D's 2024 10-K filing reveals a strategic shift towards optimizing cash flow and customer success amidst ongoing financial uncertainties and material weaknesses in internal controls.

Bluejay Diagnostics faces substantial financial challenges and is pursuing FDA approval for its Symphony platform by Q3 2028, contingent on securing significant funding and overcoming technical hurdles.